About us
Turning target engagement insights into clinical impact
Our mission?
To help scientists make better-informed decisions in lead candidate selection through biologically relevant chemical proteomics data.
Founded to close the gap between assay data & clinical outcome.
Our journey
Built on more than a decade of experience with chemical proteomics, our journey has progressed from foundational research to a company dedicated to help researchers make confident drug discovery decisions
Today, we combine scientific chemical proteomics experience with understanding the practical needs of drug discovery teams.
Building scientific foundation
Incorporation of Omivera
UNIIQ funding
Moved into BioPartner
NWO Take off 2 funding
Our team
Joel Rüegger, Co-founder & CEO
Leads Omivera’s company strategy, technology development and customer collaborations.
Anthe Janssen, Co-founder & CSO
Leads scientific strategy, assay development and data interpretation across Omivera’s platform.
Zoë Vogelaar, Co-founder & CBO
Fundraising, partnerships, intellectual property, customer development and commercial strategy.
Rob Bosman, Senior Scientist
Runs chemical proteomics studies and translates experimental data into project insights.
Advisors
Berend Gagestein, Advisor
Mass spectrometry and proteomics expert with experience in running mass spectrometry facilities in clinical settings.
Tyzoon Nomanbhoy, Advisor
Former executive at ActiveX, Tyzoon has decades of experience in mass spectrometry guided kinase research
Mario van der Stelt, Advisor
Internationally recognized chemical proteomics expert with a background in pharmaceutical industry, now professor at Leiden University.
Today
We provide biologically relevant target engagement and selectivity data to help researchers make confident decisions during lead optimization and preclinical drug development.
Tomorrow
We envision a future where target engagement becomes a routine readout throughout clinical development. By directly measuring drug target engagement in patients, developers can make dosing decisions based on quantitative evidence of target engagement, minimize unnecessary toxicity, and rapidly distinguish between insufficient target engagement and ineffective target biology. Ultimately, we believe this will enable safer and more efficient drug development.